Research shows new prognosis tool for deadly brain cancer

June 20, 2012

A diagnosis of glioblastoma multiforme (GBM) is generally a death sentence, but new research from the University of Wisconsin-Madison lab of Dr. John Kuo shows that at least one subtype is associated with a longer life expectancy. This discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.

People diagnosed with GBM live on average less than 15 months after diagnosis, even after undergoing aggressive surgery, radiation and chemotherapy. But not all GBM cancers are the same, and Kuo's study outlines a new method for sub-typing GBM tumor lines by the proteins they express.

The paper, published early online by the journal , shows that people who have a subtype of GBM that expresses a particular protein, known for short as CNP, may have a less aggressive subtype of cancer. The survival rate for those with the subtype is sometimes measured in years, not months.

The group isolated tumor lines from five human patients and grew them in the lab, and then looked for biomarkers specific to each line. They later transplanted the tissue into the brains of mice with compromised immune systems.

The researchers also looked for the CNP subtype in samples from 115 human patients and then looked at data on for those patients. They found that some patients with the protein lived much longer, as long as 10 years after diagnosis.

"We found that this protein was correlated with a less invasive type of cancer in mice, and when we looked at samples of human tumors, remarkably, we also found that the less invasive tumors expressed the CNP protein,'' says Kuo, assistant professor of and human oncology at UW School of Medicine and Public Health.

Kuo says the sub-typing could lead to more accurate prognosis for patients with a GBM diagnosis. Currently, most sub-typing of GBM tumors is based on , which can be difficult to do. But Kuo says that most hospitals can run assays for proteins, making the test simpler and easier.

In addition, says Michael Zorniak, Kuo's graduate student and lead author on the paper, the new way of typing tumors could lead to designer chemotherapy for GBM.

"As we understand how tumors are differentiated, we can start devising personalized therapies that are targeted to the specific sub-type of cancer,'' he says. "This can help us gain leverage against this difficult cancer."

For example, researchers could create monoclonal antibodies that bind only to the CNP type of cancer, in the way that some subtypes of breast cancer are currently targeted.

Explore further: Team reveals novel way to treat drug-resistant brain tumor cells

More information: The research will be published in the July issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, and is available on-line here: clincancerres.aacrjournals.org … 078-0432.CCR-12-0339

Related Stories

Team reveals novel way to treat drug-resistant brain tumor cells

June 1, 2012
New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

How brain tumors invade

December 12, 2011
Scientists have pinpointed a protein that allows brains tumors to invade healthy brain tissue, according to work published this week in the Journal of Experimental Medicine.

A thought-provoking new therapeutic target for brain cancer?

February 1, 2012
Glioblastoma multiforme (GBM) is the most common of all malignant brain tumors that originate in the brain. Patients with GBM have a poor prognosis because it is a highly aggressive form of cancer that is commonly resistant ...

One compound detects and treats malignant tumors, certain cancer stem cells

April 4, 2012
(Medical Xpress) -- More than a decade of laboratory research at the University of Wisconsin has proven that a single chemical compound may both detect and treat malignant tumors and certain cancer stem cells.

Recommended for you

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Skewing the aim of targeted cancer therapies

August 15, 2017
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

Findings pave way for three-drug combination treatment for childhood leukemia

August 15, 2017
UCLA researchers have developed a new approach that could eventually help young people respond better to treatment for acute lymphoblastic leukemia. The scientists discovered in mice that when the production of nucleotides—also ...

Does stronger initial response to cancer treatment predict longer overall survival?

August 15, 2017
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? Actually, the answer seems simple too. In ...

New study reveals late spread of breast cancer and backs key role of early diagnosis

August 14, 2017
Breast cancer cells that spread to other parts of the body break off and leave the primary tumour at late stages of disease development, scientists from the Wellcome Trust Sanger Institute and their collaborators have found.

Discovery of new prostate cancer biomarkers could improve precision therapy

August 14, 2017
Mayo Clinic researchers have identified a new cause of treatment resistance in prostate cancer. Their discovery also suggests ways to improve prostate cancer therapy. The findings appear in Nature Medicine. In the publication, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.